Income Statement (TTM)
Genflow Biosciences plc Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2023 03-31 |
2023 06-30 |
2023 09-30 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
|
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1 | 0 |
| Change (%) | 100.00 | -50.00 | 208.16 | 100.00 | -50.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| Gross Operating Profit | 0 | 0 | 0 | 0 | 1 | 0 |
| Change (%) | 100.00 | -50.00 | 208.16 | 100.00 | -50.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 2 | 2 | 2 | 2 | 2 | 2 |
| Change (%) | 3.16 | 2.29 | 3.19 | 12.22 | -3.48 | |
| % of Revenue | 1,939.29 | 1,000.33 | 2,046.45 | 685.24 | 384.50 | 742.22 |
| R&D | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| OpEx | 1 | 1 | 2 | 2 | 2 | 2 |
| Change (%) | 1.55 | 17.55 | 16.09 | 13.33 | -7.30 | |
| % of Revenue | 1,397.39 | 709.51 | 1,668.12 | 628.43 | 356.10 | 660.24 |
| Operating Income | -1 | -1 | -2 | -2 | -2 | -2 |
| Change (%) | -6.04 | 28.64 | 3.85 | -3.07 | 9.38 | |
| % of Revenue | -1,297.39 | -609.51 | -1,568.12 | -528.43 | -256.10 | -560.24 |
| Interest Expense | -0 | -0 | -0 | -0 | ||
| Change (%) | -30.82 | -17.82 | ||||
| % of Revenue | -0.30 | -0.10 | -0.17 | -0.02 | ||
| Net Income | -1 | -1 | -2 | -2 | -2 | -2 |
| Change (%) | -6.05 | 28.62 | 3.84 | -3.08 | 9.39 | |
| % of Revenue | -1,297.69 | -609.62 | -1,568.22 | -528.41 | -256.07 | -560.21 |
Source: Capital IQ
